❤️
We are so proud! Congrats to @emilyswlau 👏View quoted post on X
Mass General Brigham women’s heart health leader to receive the 2026 Dr. Nanette K. Wenger Research Goes Red® Award newsroom.heart.org/news/mass-gene…
Maria A. Pabón, MD
@mapabonp
Cardiologist @BrighamWomens @harvardmed Cardio-OB & women's health. Prior IM and Chief Resident @WeillCornell. | orgullosamente @UNALOficial y Cucuteña 🇨🇴
767 Following 1.4K Followers 931 Posts
Latest posts 5
The new @TheLancet Series on CVD in🤰 launched at #ESC2026!
Across 3 papers, the Series spans CVD in🤰→CV health across the life course
In paper #3, we focus on what comes next: how APOs signal future CVD risk, and an opportunity for earlier prevention. lnkd.in/g4Vu2jYF
Across 3 papers, the Series spans CVD in🤰→CV health across the life course
In paper #3, we focus on what comes next: how APOs signal future CVD risk, and an opportunity for earlier prevention. lnkd.in/g4Vu2jYF
Lp(a)-related VTE risk is not uniform & appears hormone-dependent: signal in premenopausal👩🦰and postmenopausal👩🦰on MHT, but not in👨🦰. Sim pub with #ACC.26 @ehj_ed. Congrats @daniel_ezt and 🙏 to co-authors & my co-senior author, mentor & friend @mchonig
academic.oup.com/eurheartj/adva…
academic.oup.com/eurheartj/adva…
New: @ehj_ed @ESC_Journals in FINE-HEART, 👩🦰 with CKM sx had a ⬆️ burden of multimorbidity but ⬇️ likely to receive indicated CKM therapies than 👨🦰, despite similarly high risks of adverse outcomes. Finerenone had similar benefits. @mvaduganathan academic.oup.com/eurheartj/adva…
APOs and cardiometabolic risk are tightly linked. In our new HCHS/SOL analysis published in @AJPCardio, preconception cardiometabolic abnormalities were associated with higher odds of APOs, with a clear dose response by metabolic syndrome burden. @OdaymeMD sciencedirect.com/science/articl…
